| # | Title | Journal | Year | Citations |
|---|
| 1 | Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study | The Lancet Gastroenterology and Hepatology | 2017 | 1,619 |
| 2 | Liver injury in COVID-19: management and challenges | The Lancet Gastroenterology and Hepatology | 2020 | 1,475 |
| 3 | Prolonged presence of SARS-CoV-2 viral RNA in faecal samples | The Lancet Gastroenterology and Hepatology | 2020 | 1,345 |
| 4 | Global prevalence, treatment, and prevention of hepatitis B virus infection in 2016: a modelling study | The Lancet Gastroenterology and Hepatology | 2018 | 1,241 |
| 5 | The global, regional, and national burden of inflammatory bowel disease in 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017 | The Lancet Gastroenterology and Hepatology | 2020 | 1,200 |
| 6 | The global, regional, and national burden of cirrhosis by cause in 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017 | The Lancet Gastroenterology and Hepatology | 2020 | 823 |
| 7 | Manifestations and prognosis of gastrointestinal and liver involvement in patients with COVID-19: a systematic review and meta-analysis | The Lancet Gastroenterology and Hepatology | 2020 | 804 |
| 8 | Enteric involvement of coronaviruses: is faecal–oral transmission of SARS-CoV-2 possible? | The Lancet Gastroenterology and Hepatology | 2020 | 654 |
| 9 | Prevalence, incidence, and outcome of non-alcoholic fatty liver disease in Asia, 1999–2019: a systematic review and meta-analysis | The Lancet Gastroenterology and Hepatology | 2019 | 616 |
| 10 | The prevalence and incidence of NAFLD worldwide: a systematic review and meta-analysis | The Lancet Gastroenterology and Hepatology | 2022 | 566 |
| 11 | Global prevalence, incidence, and outcomes of non-obese or lean non-alcoholic fatty liver disease: a systematic review and meta-analysis | The Lancet Gastroenterology and Hepatology | 2020 | 481 |
| 12 | Global incidence and mortality of pancreatic diseases: a systematic review, meta-analysis, and meta-regression of population-based cohort studies | The Lancet Gastroenterology and Hepatology | 2016 | 442 |
| 13 | Predictors of anti-TNF treatment failure in anti-TNF-naive patients with active luminal Crohn's disease: a prospective, multicentre, cohort study | The Lancet Gastroenterology and Hepatology | 2019 | 431 |
| 14 | FibroScan-AST (FAST) score for the non-invasive identification of patients with non-alcoholic steatohepatitis with significant activity and fibrosis: a prospective derivation and global validation study | The Lancet Gastroenterology and Hepatology | 2020 | 411 |
| 15 | The microbiota–gut–brain axis in obesity | The Lancet Gastroenterology and Hepatology | 2017 | 408 |
| 16 | SARS-CoV-2 in wastewater: potential health risk, but also data source | The Lancet Gastroenterology and Hepatology | 2020 | 406 |
| 17 | A watch-and-wait approach for locally advanced rectal cancer after a clinical complete response following neoadjuvant chemoradiation: a systematic review and meta-analysis | The Lancet Gastroenterology and Hepatology | 2017 | 399 |
| 18 | Laparoscopic versus open pancreatoduodenectomy for pancreatic or periampullary tumours (LEOPARD-2): a multicentre, patient-blinded, randomised controlled phase 2/3 trial | The Lancet Gastroenterology and Hepatology | 2019 | 393 |
| 19 | The global, regional, and national burden of stomach cancer in 195 countries, 1990–2017: a systematic analysis for the Global Burden of Disease study 2017 | The Lancet Gastroenterology and Hepatology | 2020 | 390 |
| 20 | Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of patients with HBeAg-negative chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial | The Lancet Gastroenterology and Hepatology | 2016 | 377 |
| 21 | The global, regional, and national burden of pancreatic cancer and its attributable risk factors in 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017 | The Lancet Gastroenterology and Hepatology | 2019 | 372 |
| 22 | COVID-19 and the liver: little cause for concern | The Lancet Gastroenterology and Hepatology | 2020 | 371 |
| 23 | Accelerating the elimination of viral hepatitis: a Lancet Gastroenterology & Hepatology Commission | The Lancet Gastroenterology and Hepatology | 2019 | 370 |
| 24 | Sorafenib in combination with transarterial chemoembolisation in patients with unresectable hepatocellular carcinoma (TACE 2): a randomised placebo-controlled, double-blind, phase 3 trial | The Lancet Gastroenterology and Hepatology | 2017 | 362 |
| 25 | Global prevalence of irritable bowel syndrome according to Rome III or IV criteria: a systematic review and meta-analysis | The Lancet Gastroenterology and Hepatology | 2020 | 359 |
| 26 | Pathophysiology of irritable bowel syndrome | The Lancet Gastroenterology and Hepatology | 2016 | 358 |
| 27 | A global scientific strategy to cure hepatitis B | The Lancet Gastroenterology and Hepatology | 2019 | 342 |
| 28 | Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of HBeAg-positive chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial | The Lancet Gastroenterology and Hepatology | 2016 | 336 |
| 29 | Faecal microbiota transplantation versus placebo for moderate-to-severe irritable bowel syndrome: a double-blind, randomised, placebo-controlled, parallel-group, single-centre trial | The Lancet Gastroenterology and Hepatology | 2018 | 325 |
| 30 | Liver diseases in the Asia-Pacific region: a Lancet Gastroenterology & Hepatology Commission | The Lancet Gastroenterology and Hepatology | 2020 | 320 |
| 31 | Type 3c (pancreatogenic) diabetes mellitus secondary to chronic pancreatitis and pancreatic cancer | The Lancet Gastroenterology and Hepatology | 2016 | 318 |
| 32 | Personalised versus standard dosimetry approach of selective internal radiation therapy in patients with locally advanced hepatocellular carcinoma (DOSISPHERE-01): a randomised, multicentre, open-label phase 2 trial | The Lancet Gastroenterology and Hepatology | 2021 | 307 |
| 33 | Effect of a deep-learning computer-aided detection system on adenoma detection during colonoscopy (CADe-DB trial): a double-blind randomised study | The Lancet Gastroenterology and Hepatology | 2020 | 276 |
| 34 | Implications of COVID-19 for patients with pre-existing digestive diseases | The Lancet Gastroenterology and Hepatology | 2020 | 274 |
| 35 | Changes in colorectal cancer incidence in seven high-income countries: a population-based study | The Lancet Gastroenterology and Hepatology | 2019 | 261 |
| 36 | The global, regional, and national burden of colorectal cancer and its attributable risk factors in 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017 | The Lancet Gastroenterology and Hepatology | 2019 | 259 |
| 37 | Early detection of pancreatic cancer | The Lancet Gastroenterology and Hepatology | 2020 | 258 |
| 38 | Prevalence of symptoms of anxiety and depression in patients with inflammatory bowel disease: a systematic review and meta-analysis | The Lancet Gastroenterology and Hepatology | 2021 | 256 |
| 39 | Country, regional, and global estimates for lactose malabsorption in adults: a systematic review and meta-analysis | The Lancet Gastroenterology and Hepatology | 2017 | 253 |
| 40 | Detection of colorectal adenomas with a real-time computer-aided system (ENDOANGEL): a randomised controlled study | The Lancet Gastroenterology and Hepatology | 2020 | 251 |
| 41 | Impact of the COVID-19 pandemic on the detection and management of colorectal cancer in England: a population-based study | The Lancet Gastroenterology and Hepatology | 2021 | 244 |
| 42 | The global, regional, and national burden of oesophageal cancer and its attributable risk factors in 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017 | The Lancet Gastroenterology and Hepatology | 2020 | 241 |
| 43 | Primary antibiotic resistance in Helicobacter pylori in the Asia-Pacific region: a systematic review and meta-analysis | The Lancet Gastroenterology and Hepatology | 2017 | 238 |
| 44 | Global change in hepatitis C virus prevalence and cascade of care between 2015 and 2020: a modelling study | The Lancet Gastroenterology and Hepatology | 2022 | 237 |
| 45 | The mesentery: structure, function, and role in disease | The Lancet Gastroenterology and Hepatology | 2016 | 235 |
| 46 | Sofosbuvir and velpatasvir for hepatitis C virus infection in people with recent injection drug use (SIMPLIFY): an open-label, single-arm, phase 4, multicentre trial | The Lancet Gastroenterology and Hepatology | 2018 | 231 |
| 47 | Somatic POLE proofreading domain mutation, immune response, and prognosis in colorectal cancer: a retrospective, pooled biomarker study | The Lancet Gastroenterology and Hepatology | 2016 | 227 |
| 48 | Non-alcoholic fatty liver disease and risk of fatal and non-fatal cardiovascular events: an updated systematic review and meta-analysis | The Lancet Gastroenterology and Hepatology | 2021 | 227 |
| 49 | Nivolumab alone or in combination with cisplatin plus gemcitabine in Japanese patients with unresectable or recurrent biliary tract cancer: a non-randomised, multicentre, open-label, phase 1 study | The Lancet Gastroenterology and Hepatology | 2019 | 223 |
| 50 | Hepatitis B in sub-Saharan Africa: strategies to achieve the 2030 elimination targets | The Lancet Gastroenterology and Hepatology | 2017 | 217 |
